The queried claim ('Alpha-synuclein Ensemble Validation NMR SAXS Cryo-EM for IDP Prediction') is not supported by any supplied record. The seven records cover: Sic1 integrative ensembles , Bayesian ensemble inference from SAXS , hybrid-resolution SAXS-restrained MD , and an alpha-synuclein tubulin-interaction study . Missing: alpha-synuclein conformational ensemble data, Cryo-EM structures of monomeric alpha-synuclein (cryo-EM of IDP monomers is itself near-impossible due to sub-nanometer heterogeneity), and any alpha-synuclein-specific validation datasets.
The Sic1 study demonstrates the critical failure mode: SAXS-only and smFRET-only ensembles disagreed on Ree (76 vs 61-65 Γ ), and only joint restraints converged . Any alpha-synuclein claim relying on one technique inherits this ambiguity. Known blind spots across methods: PRE r-6 weighting over-weights compact states; low SAXS information content (11 restraint points sufficed for K63-Ub2 but left PRE overestimations for some interfaces) ; and Kish effective sample sizes as low as 2.9 in maximum-entropy reweighting .
Predicted vs experimental Rg agreement from the SAXS-guided sampling record shows MD+ensemble methods can recover folded-protein dimensions within 0.1-0.3 Γ , but these are folded controls β not IDP ensemble predictions .
To battle-test such a claim: (1) deposit alpha-synuclein SAXS/PRE/CS data and run joint ENSEMBLE or metainference fitting; (2) require agreement with an independent technique not used in fitting (as Sic1 did with smFRET); (3) report Kish sizes and chi2 outside the fitted q-range; (4) note that cryo-EM resolves only aggregated alpha-synuclein fibrils, not the monomeric IDP ensemble. Confidence in this critique: high (evidence-record scope is unambiguous); confidence that no such alpha-synuclein study exists anywhere: low β only that none is supplied here.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.